Newswise — April 8, 2021 – Women undergoing surgery to treat stress urinary incontinence (SUI) are not at increased risk of developing pelvic cancers, according to a large-scale, population-based study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

"In a very large population with extended follow-up, we found no increase in the risk of any pelvic malignancy in women who underwent stress urinary incontinence surgery," comments lead author Humberto R. Vigil, MD, MSc, of University of Ottawa, Ont., Canada. "The vast majority of stress urinary incontinence procedures performed included transvaginal mesh."

No increase in cancers after SUI surgery – with or without transvaginal mesh 

Using Ontario health data, the researchers identified nearly 75,000 women who underwent SUI surgery between 2002 and 2015. Follow-up data (median 8.5 years) were used to assess for the development of pelvic cancers, such as bladder, cervical and ovarian cancer. A time to event analysis was used to determine the risk of pelvic cancer in SUI surgery patients compared to more than 5.5 million women who did not undergo SUI surgery.

On analysis of more than 40,000 pelvic cancers, there was no significant difference between groups. The event rate for pelvic malignancies was 0.90 per 1,000 person-years of follow-up in women undergoing SUI surgery, compared to 0.85 per 1,000 person-years in controls who did not have surgery.

After adjustment for multiple factors, there was a lower risk of pelvic cancers in women who underwent SUI surgery. While that may seem like a paradoxical finding, Dr. Vigil and colleagues suggest a couple of possible explanations: women opting for an elective procedure such as SUI surgery may be relatively healthier (selection bias), or cancers might be detected during assessment before SUI surgery. The study confirmed some known risk factors for pelvic cancers, including obesity and no history of childbirth.

Importantly, there was no evidence of increased cancer risk in women undergoing SUI surgery with implanted transvaginal mesh. A midurethral sling procedure using polypropylene mesh is the most commonly performed surgery for SUI. 

Over the past decade, there have been public health concerns regarding complications and safety issues related to surgical mesh – particularly related to a condition called pelvic organ prolapse (POP), but also for SUI. These issues have led to some individuals being hesitant to move forward with mesh-based procedures. In the study data, more than 85 percent of women undergoing SUI surgery had a mesh-based procedure. 

The new analysis may help to alleviate some patient concerns. "Our population-based study finds no evidence of increased risk of pelvic cancers following SUI surgery, with or without the use of transvaginal mesh," Dr. Vigil comments. "Providers can confidently reassure women regarding the lack of association.”  

Click here to read “Stress Incontinence Surgery Does Not Cause Pelvic Malignancy: A Population-Based Cohort Study.”

DOI: 10.1097/JU.0000000000001631


About The Journal of Urology®

The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit:

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit and follow us on LinkedIn and Twitter @WKHealth.


For more information, visit, follow us on TwitterFacebookLinkedIn, and YouTube.



Journal Link: Journal of Urology, DOI: 10.1097/JU.0000000000001631